Aging Population And Precision Medicine Will Expand Oncology Opportunities
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
06 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$47.00
77.7% undervalued intrinsic discount16 Aug
US$10.47
1Y
-39.5%7D
14.3%